IMDX vs MDXH
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
IMDX exhibits severe financial distress, anchored by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. The company suffers from negative equity (Price/Book: -2.89) and a catastrophic operating margin of -873.57%, suggesting an unsustainable business model. Revenue is contracting rapidly (-23.4% YoY), and the earnings track record is abysmal with 0 beats in the last four quarters. Despite optimistic analyst price targets, the deterministic data points toward a high risk of insolvency or significant further dilution.
MDXH exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -9.30, indicating negative shareholder equity. While the company maintains a strong gross margin (64.55%) and positive revenue growth (~19%), these are completely offset by catastrophic ROE (-2440%) and a consistent track record of missing earnings estimates (0/4 beats in the last year). The technical trend is purely bearish, and the lack of a valid Altman Z-Score combined with poor liquidity ratios suggests a high risk of insolvency.
Compare Another Pair
Related Comparisons
IMDX vs MDXH: Head-to-Head Comparison
This page compares Insight Molecular Diagnostics Inc. (IMDX) and MDxHealth SA (MDXH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.